Completed PHASE4 INTERVENTIONAL 2-arm NCT00615810

ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial (ROCKET I)

A Phase 4, Open Label, Randomized, Controlled Study to Assess the Effect on Lipid Profile of Switching From a Stable HAART Regimen of Fixed Dose Abacavir/Lamivudine (Kivexa) Plus Efavirenz, to Once Daily Atripla in Adult HIV-1 Infected Subjects With Raised Cholesterol

Sponsor: Gilead Sciences

Conditions HIV Infections

Interventions Atripla Kivexa plus Sustiva

Updated 5 times since 2017 Last updated: Jul 30, 2010 Started: Mar 31, 2008 Primary completion: Oct 31, 2009 Completion: Jan 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates HIV Infections and is currently completed. Gilead Sciences leads this study, which shows 5 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gilead Sciences

Data source: Gilead Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Granta Park, Cambridge, United Kingdom